Granite Point Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Granite Point Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-40,000	Closed	-$745K	–	156
2021 Q3	$745K	Sell	40,000 -10,000	-20%	-$190K	0.06%	104
2021 Q2	$1.06M	Buy	+50,000	New	+$1.15M	0.04%	115

Other funds holding TSHA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Granite Point Capital Management's TSHA Position: Q4 2021 in Review

Granite Point Capital Management sold out of Taysha Gene Therapies (TSHA) in Q4 2021, closing a stake of 40,000 shares — an estimated $745K sold.

Granite Point Capital Management first reported a position in TSHA in Q2 2021 and held it in 2 quarters. The position peaked at $1.06M in Q2 2021. 65 funds tracked by Wall St. Rank hold TSHA as of Q4 2021.

Granite Point Capital Management reported no remaining Taysha Gene Therapies position as of Q4 2021 after selling out during the quarter.
Granite Point Capital Management sold 40,000 Taysha Gene Therapies shares in Q4 2021, an estimated $745K.
Granite Point Capital Management first reported a position in Taysha Gene Therapies in Q2 2021 and held it in 2 quarters.
Granite Point Capital Management's Taysha Gene Therapies position peaked at $1.06M in Q2 2021.
65 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2021.

Based on Granite Point Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.